In brief
This NIH RePORTER record details a Research Career Scientist Award (5IK6RX002991-07) held by KATH BOGIE, focusing on developing and evaluating novel approaches to reduce fear of chronic non-healing wounds in Veterans. The research involves interdisciplinary studies on pressure injury prevention, including...
What this article is about
Quick Answer
This NIH RePORTER record details a Research Career Scientist Award (5IK6RX002991-07) held by KATH BOGIE, focusing on developing and evaluating novel approaches to reduce fear of chronic non-healing wounds in Veterans. The research involves interdisciplinary studies on pressure injury prevention, including personalized risk assessment using biomarkers for those with spinal cord injuries (SCI), development of a point-of-care LAMP platform technology for rapid risk identification, and creation of the flexSTIM device for dynamic gluteal stimulation to aid pressure relief and musculoskeletal health. The work also includes developing an electroceutical bandage (exciflex) for wound healing and aims to mentor emerging leaders in chronic wound management research within the Veteran population.
Student takeaways
Key Takeaways
- The database record does not provide key finding 1.
- The database record does not provide key finding 2.
- The database record does not provide key finding 3.
- The database record does not provide key finding 4.
- The database record does not provide key finding 5.
Student summary
Why This Research Matters
This document provides a detailed overview of the research activities and career trajectory of Dr. KATH BOGIE, who holds an RR&D Research Career Scientist Award (ID: 5IK6RX002991-07) from the US Department of Veterans Affairs. The primary goal of her extensive work is to develop and evaluate innovative, clinically-focused strategies aimed at reducing the fear associated with chronic non-healing wounds and their secondary health complications among veterans.
Dr. Bogie's research portfolio is multifaceted and interdisciplinary. A significant portion involves personalized pressure injury (PrI) risk assessment through the identification of novel biomarkers. This work includes a current VA Merit Review project investigating factors contributing to recurrent PrIs in individuals with spinal cord injuries (SCI). Her team has discovered that persons experiencing recurrent PrIs exhibit upregulated activity in genomic variants linked to fatty acid metabolism, which represents a significant paradigm shift in primary PrI prevention strategies.
Building on these findings, Dr. Bogie's research is developing point-of-care technologies for rapid identification of individuals at increased risk of recurrent PrIs. One such technology utilizes a novel reverse-transcription LAMP platform. Concurrently, she leads the development of flexSTIM, a biomimetic flexible implanted pattern generator designed to deliver dynamic intermittent gluteal stimulation (iGSTIM). This device aims to enable regular exercise and weight-shifting for Veterans with SCI who are unable to perform independent pressure relief or have poor muscle quality, thereby addressing fundamental challenges in PrI prevention and musculoskeletal health.
Another key area of her research focuses on wound healing technologies. The VA has patented the exciflex wearable programmable electroceutical bandage, which significantly increases wound closure rates and decreases infection risk by enabling safe and smart delivery of electrotherapy outside traditional clinical settings. A current clinical feasibility study is underway to further validate its use for personalized adaptive electrotherapy.
Dr. Bogie's approach to translational technology development has been highly successful, evidenced by her extensive portfolio: 10 issued patents (including one European patent), 4 pending US patents, 7 pending PCT patents, and 3 recent invention disclosures. This reflects a strong commitment to bringing research discoveries into practical applications for patient benefit.
Her professional accomplishments are substantial, including continuous funding from various prestigious organizations such as the VA Rehabilitation Service, DoD SCI Research Program, Craig H. Neilsen Foundation, and Paralyzed Veterans of America over more than 20 years. In recognition of her outstanding contributions to wound biotechnology development and patient-centered pressure injury management, she was elected a Fellow of the American Institute for Medical and Biological Engineering in 2021.
Dr. Bogie has an extensive publication record with over 80 papers, chapters, and reviews published, including 22 peer-reviewed manuscripts during her most recent period of Research Career Scientist support. She has also contributed significantly to research ethics and governance by serving for 16 years as a member of the local Institutional Review Board (IRB) and on multiple VA and NIH grant review panels.
Looking ahead, Dr. Bogie's professional goals for the upcoming renewal period of her Research Career Scientist Award are twofold: first, to continue developing and implementing translational team science research in the underrecognized area of chronic wound management; and second, to mentor emerging leaders in the field, thereby enabling novel solutions and personalized primary prevention strategies specifically tailored for the most susceptible individuals within the high-risk population of Veterans. Her work underscores a deep commitment to improving patient outcomes through innovative research and dedicated mentoring.
Source abstract
Study Overview
The over-arching goal of my research activity is to develop and evaluate novel clinically-focused approaches to reduce the fear of developing chronic non-healing wounds and associated secondary health complications. I am a Research Career Scientist in the RR&D Service of the US Department of Veterans Affairs and dually appointed as Professor of Orthopaedics and Biomedical Engineering at Case Western Reserve University. Active interdisciplinary clinical studies include determination of personalized pressure injury (PrI) risk based on identification of novel biomarkers. A current VA Merit Review project is investigating the factors driving recurrent PrI in persons with SCI. We have found that persons with recurrent PrI have upregulated activity in genomic variants associated with fatty acid metabolism. This paradigm shift in primary PrI prevention was recognized with a 2nd place Best Oral Talk Award from the American Spinal Injury Association in 2022. These findings also provide the foundation for development of a point-of-care technology to rapidly identify individuals at increased risk of recurrent PrI based on a novel reverse-transcription LAMP platform. Current technology development studies include of development the flexSTIM, biomimetic flexible novel implanted pattern generator for dynamic intermittent gluteal stimulation (iGSTIM) enabling regular exercise and weight-shifting. iGSTIM impacts fundamental challenges in PrI prevention and musculoskeletal heath for Veterans with SCI, particularly those who cannot perform independent pressure relief and those with poor muscle quality. A VA Translational Rehabilitation Research Award: Stage 1 (TRRA-1) is supporting the next steps in delivering this VA research discovery to a new treatment for Veterans with reduced mobility. Unfortunately, chronic wounds still continue to occur all too frequently. The VA patented exciflex wearable programmable, electroceutical bandage significantly increases wound closure rates and decreases infection enabling safe and smart delivery of electrotherapy outside traditional clinical settings. A clinical feasibility study is underway and will provide a strong foundation for delivery of personalized adaptive electrotherapy using exciflex, so that our Veterans will benefit from the most recent advances in wound healing science. My approach to translational technology includes 10 issued patents, including one European patent, together with 4 pending US patents, 7 pending PCT patents and 3 recent invention disclosures. I have over 20 years continuous funding from the VA Rehabilitation Service, DoD SCI Research Program, the Craig H. Neilsen Foundation and the Paralyzed Veterans of America. In recognition of the significance of my research, I was elected Fellow of the American Institute for Medical and Biological Engineering in 2021, recognized for outstanding contributions to wound biotechnology development and patient-centered pressure injury management. I have over published 80 papers, chapters and reviews, including 22 peer-reviewed manuscripts that were published during my most recent period of Research Career Scientist support. I have served for 16 years as a member of the local IRB and served as a member of the Advisory Committee for the VISN8 Patient Safety Center of Inquiry in addition to serving on multiple VA and NIH grant review panels. I am working with the VA Office of Nursing Services to set up a Interprofessional Pressure Injury Research Roundtable and am also active in leading professional organizations in my field including the Wound Healing Society (Chair of the Education Committee) and the National Pressure Injury Advisory Panel (Board of Directors). I am Editor-in- Chief for the Journal of Rehabilitation and Assistive Technologies Engineering. My professional goals during the upcoming renewal period of my Research Career Scientist Award are to continue to develop and implement translational team science research in the underrecognized area of chronic wound management and to mentor emerging leaders in the field, enabling novel solutions and personalized primary prevention for the most susceptible individuals within the high-risk population of Veterans.
Evidence appraisal
Main Findings
- The database record does not provide key finding 1.
- The database record does not provide key finding 2.
- The database record does not provide key finding 3.
- The database record does not provide key finding 4.
- The database record does not provide key finding 5.
Practice transfer
Clinical Relevance
- Clinical implication 1 should be interpreted cautiously because the database record is limited.
- Clinical implication 2 should be interpreted cautiously because the database record is limited.
- Clinical implication 3 should be interpreted cautiously because the database record is limited.
- Clinical implication 4 should be interpreted cautiously because the database record is limited.
- Clinical implication 5 should be interpreted cautiously because the database record is limited.
Faculty notes
Educational Relevance
RR&D Research Career Scientist Award can be used for source-grounded discussion. The database record does not provide enough detail for a fuller faculty summary.
Critical appraisal
Limitations
- The database record does not provide limitation 1.
- The database record does not provide limitation 2.
- The database record does not provide limitation 3.
Classroom use
Discussion Questions
- Discussion question 1: What does "RR&D Research Career Scientist Award" help nursing students evaluate?
- Discussion question 2: What does "RR&D Research Career Scientist Award" help nursing students evaluate?
- Discussion question 3: What does "RR&D Research Career Scientist Award" help nursing students evaluate?
- Discussion question 4: What does "RR&D Research Career Scientist Award" help nursing students evaluate?
- Discussion question 5: What does "RR&D Research Career Scientist Award" help nursing students evaluate?
- Discussion question 6: What does "RR&D Research Career Scientist Award" help nursing students evaluate?
- Discussion question 7: What does "RR&D Research Career Scientist Award" help nursing students evaluate?
- Discussion question 8: What does "RR&D Research Career Scientist Award" help nursing students evaluate?
- Discussion question 9: What does "RR&D Research Career Scientist Award" help nursing students evaluate?
- Discussion question 10: What does "RR&D Research Career Scientist Award" help nursing students evaluate?
Search-ready answers
Frequently asked questions
What is the primary goal of Dr. Bogie's research activity described in this NIH RePORTER record?
The over-arching goal of my research activity is to develop and evaluate novel clinically-focused approaches to reduce the fear of developing chronic non-healing wounds and associated secondary health complications.
In which organization(s) is Dr. KATH BOGIE dually appointed, as mentioned in their NIH RePORTER abstract?
Dr. KATH BOGIE is dually appointed as Professor of Orthopaedics and Biomedical Engineering at Case Western Reserve University.
What specific type of injury risk are the active interdisciplinary clinical studies focused on determining personalized risk for based on novel biomarkers, according to the NIH RePORTER abstract?
The active interdisciplinary clinical studies include determination of personalized pressure injury (PrI) risk based on identification of novel biomarkers.
Which VA Merit Review project is investigating factors driving recurrent PrI in persons with SCI, as stated in the NIH RePORTER abstract?
A current VA Merit Review project is investigating the factors driving recurrent PrI in persons with SCI.
What significant finding related to fatty acid metabolism was discovered concerning individuals with recurrent pressure injuries (PrIs), according to the NIH RePORTER abstract?
We have found that persons with recurrent PrI have upregulated activity in genomic variants associated with fatty acid metabolism.
For what purpose is a point-of-care technology being developed based on findings related to recurrent PrI risk, as described in the NIH RePORTER abstract?
These findings also provide the foundation for development of a point-of-care technology to rapidly identify individuals at increased risk of recurrent PrI.
What innovative device called 'flexSTIM' is mentioned in the NIH RePORTER abstract related to dynamic intermittent gluteal stimulation (iGSTIM)?
Current technology development studies include of development the flexSTIM, biomimetic flexible novel implanted pattern generator for dynamic intermittent gluteal stimulation (iGSTIM).
Which organization is supporting the next steps in delivering the VA research discovery related to flexSTIM as a new treatment?
A VA Translational Rehabilitation Research Award: Stage 1 (TRRA-1) is supporting the next steps in delivering this VA research discovery to a new treatment for Veterans with reduced mobility.
What patented wearable device significantly increases wound closure rates and decreases infection, enabling safe and smart delivery of electrotherapy outside traditional clinical settings?
The VA patented exciflex wearable programmable, electroceutical bandage significantly increases wound closure rates and decreases infection.
Which professional organization is Dr. KATH BOGIE currently serving as Editor-in-Chief for, according to the NIH RePORTER abstract?
I am Editor-in-Chief for the Journal of Rehabilitation and Assistive Technologies Engineering.